LCMV-GP-VSV-pseudotyped vectors and tumor-infiltrating virus-producing cells for the therapy of tumors
AssigneeViratherapeutics GmbH
InventorsDorothee Von Laer, Tsanan Heimann
Life of this patent
Estimating the term…
Abstract
The invention relates to recombinant VSV viruses and viral vectors which produce a glycoprotein GP of the lymphocyte choriomeningitis virus (LCMV) instead of the G protein of the VSV, to virus producing cells which produce LCMV-GP-pseudotyped VSV virions, and to the use of said vectors and cells in the therapy of solid tumors, especially brain tumors.
Claims24
A tumor-specific replication-competent VSV-LCMV-GP pseudotype vector system, characterized in that the system comprises at least two complementary replicating VSV vectors, wherein the system comprises genes n, l, p and m coding for proteins N, L, P and M of the VSV, a gene gp coding for LCMV GP and lacks a functional gene coding for G protein of the VSV, wherein each vector of the system lacks one of the genes n, l, p, m and gp, and wherein the lacking gene is present on any other vector of the system, wherein infection of cells with the at least two complementary replicating VSV vectors causes LCMV-GP to be encoded in the genome of at least one progeny viral particle and subsequently expressed on the surface of the at least one progeny viral particle;
- and wherein tropism of the progeny viral particle is independent of an additional tumor-targeting element or transgene in the VSV-LCMV-GP pseudotype vector system.
Dependencies are inferred from the claim text.